FLGT Quote, Financials, Valuation and Earnings

CytoSorbents Corp. has a net margin of -28.38% compared to Fulgent Genetics, Inc.'s net margin of -59.53%. Fulgent Genetics, Inc.'s return on equity of -5.51% beat CytoSorbents Corp.'s return on equity of -78.59%.

Fulgent Genetics, Inc. has a consensus price target of $24.33, signalling upside risk potential of 44.67%. On the other hand CytoSorbents Corp. has an analysts' consensus of $5.25 which suggests that it could grow by 800.52%. Given that CytoSorbents Corp. has higher upside potential than Fulgent Genetics, Inc., analysts believe CytoSorbents Corp. is more attractive than Fulgent Genetics, Inc..

Fulgent Genetics, Inc. has a beta of 0.892, which suggesting that the stock is 10.775% less volatile than S&P 500. In comparison CytoSorbents Corp. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.189%.

Fulgent Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CytoSorbents Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics, Inc. pays -- of its earnings as a dividend. CytoSorbents Corp. pays out -- of its earnings as a dividend.

Fulgent Genetics, Inc. quarterly revenues are $83.3M, which are larger than CytoSorbents Corp. quarterly revenues of $9.2M. Fulgent Genetics, Inc.'s net income of -$23.7M is lower than CytoSorbents Corp.'s net income of -$5.5M. Notably, Fulgent Genetics, Inc.'s price-to-earnings ratio is -- while CytoSorbents Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics, Inc. is 1.64x versus 1.00x for CytoSorbents Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Delcath Systems, Inc. has a net margin of -28.38% compared to Fulgent Genetics, Inc.'s net margin of -9.15%. Fulgent Genetics, Inc.'s return on equity of -5.51% beat Delcath Systems, Inc.'s return on equity of 2.81%.

Fulgent Genetics, Inc. has a consensus price target of $24.33, signalling upside risk potential of 44.67%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $21.33 which suggests that it could grow by 121.53%. Given that Delcath Systems, Inc. has higher upside potential than Fulgent Genetics, Inc., analysts believe Delcath Systems, Inc. is more attractive than Fulgent Genetics, Inc..

Fulgent Genetics, Inc. has a beta of 0.892, which suggesting that the stock is 10.775% less volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.439, suggesting its less volatile than the S&P 500 by 56.086%.

Fulgent Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

Fulgent Genetics, Inc. quarterly revenues are $83.3M, which are larger than Delcath Systems, Inc. quarterly revenues of $20.7M. Fulgent Genetics, Inc.'s net income of -$23.7M is lower than Delcath Systems, Inc.'s net income of -$1.9M. Notably, Fulgent Genetics, Inc.'s price-to-earnings ratio is -- while Delcath Systems, Inc.'s PE ratio is 154.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics, Inc. is 1.64x versus 4.45x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics, Inc. has a net margin of -28.38% compared to Fulgent Genetics, Inc.'s net margin of 9.12%. Fulgent Genetics, Inc.'s return on equity of -5.51% beat Quest Diagnostics, Inc.'s return on equity of 14.49%.

Fulgent Genetics, Inc. has a consensus price target of $24.33, signalling upside risk potential of 44.67%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $218.50 which suggests that it could grow by 10.34%. Given that Fulgent Genetics, Inc. has higher upside potential than Quest Diagnostics, Inc., analysts believe Fulgent Genetics, Inc. is more attractive than Quest Diagnostics, Inc..

Fulgent Genetics, Inc. has a beta of 0.892, which suggesting that the stock is 10.775% less volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.067%.

Fulgent Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.61% to investors and pays a quarterly dividend of $0.80 per share. Fulgent Genetics, Inc. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 36.6% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Fulgent Genetics, Inc. quarterly revenues are $83.3M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. Fulgent Genetics, Inc.'s net income of -$23.7M is lower than Quest Diagnostics, Inc.'s net income of $256M. Notably, Fulgent Genetics, Inc.'s price-to-earnings ratio is -- while Quest Diagnostics, Inc.'s PE ratio is 22.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics, Inc. is 1.64x versus 2.03x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Odyssey Health, Inc. has a net margin of -28.38% compared to Fulgent Genetics, Inc.'s net margin of --. Fulgent Genetics, Inc.'s return on equity of -5.51% beat Odyssey Health, Inc.'s return on equity of --.

Fulgent Genetics, Inc. has a consensus price target of $24.33, signalling upside risk potential of 44.67%. On the other hand Odyssey Health, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Fulgent Genetics, Inc. has higher upside potential than Odyssey Health, Inc., analysts believe Fulgent Genetics, Inc. is more attractive than Odyssey Health, Inc..

Fulgent Genetics, Inc. has a beta of 0.892, which suggesting that the stock is 10.775% less volatile than S&P 500. In comparison Odyssey Health, Inc. has a beta of -1.363, suggesting its less volatile than the S&P 500 by 236.315%.

Fulgent Genetics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Odyssey Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fulgent Genetics, Inc. pays -- of its earnings as a dividend. Odyssey Health, Inc. pays out -- of its earnings as a dividend.

Fulgent Genetics, Inc. quarterly revenues are $83.3M, which are larger than Odyssey Health, Inc. quarterly revenues of --. Fulgent Genetics, Inc.'s net income of -$23.7M is lower than Odyssey Health, Inc.'s net income of -$3.6M. Notably, Fulgent Genetics, Inc.'s price-to-earnings ratio is -- while Odyssey Health, Inc.'s PE ratio is 0.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fulgent Genetics, Inc. is 1.64x versus -- for Odyssey Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.